Related Experiment Videos
Managing borderline levels of risk for coronary heart disease: two illustrative case presentations
1Division of General Internal Medicine and Health Services Research, UCLA Center for Primary Care-Based Cardiovascular Disease Prevention, UCLA School of Medicine, Los Angeles, Calif., USA.
Insights
New guidelines for coronary heart disease (CHD) treatment are complex. Case studies show balancing trial data with clinical judgment is key for borderline risk patients needing cholesterol therapy.
Area of Science:
- Cardiology
- Public Health
Background:
- The National Cholesterol Education Program (NCEP) Adult Treatment Panel II (ATP II) guidelines were published in 1993.
- Recent data and the ATP III guidelines have increased complexity in clinical decision-making for coronary heart disease (CHD).
Observation:
- Many common patient profiles do not fit neatly into established risk categories.
- Clinical decisions are challenged by the sheer volume of new research data.
Findings:
- Case studies demonstrate the need to integrate recent trial data with clinical expertise.
- This integration is crucial for initiating cholesterol-lowering therapy in patients with borderline risk levels.
Implications:
- This approach supports both primary and secondary prevention strategies for CHD.
- Enhanced clinical judgment alongside data improves patient management for cardiovascular health.
Abstract:
Much has been learned about preventing and treating coronary heart disease (CHD) since publication of the National Cholesterol Education Program (NCEP) Adult Treatment Panel II (ATP II) guidelines in 1993. Even with the recent release of the ATP III guidelines, clinical decision making has become increasingly complex as a result of the tremendous volume of new data, and because many common patient types do not fit precisely into the defined risk categories. The case studies presented here illustrate how data from recent trials and the clinician's judgment should be weighed together in the decision to initiate cholesterol-lowering therapy in patients with borderline risk levels, as part of a strategy for primary and secondary prevention of CHD.
Related Concept Videos
Coronary Artery Disease IV: Preventive Measures
Coronary Artery Disease I: Introduction
Atherosclerosis III: Management
Coronary Artery Disease V: Interprofessional Care
Atherosclerosis IV: Nursing Management
Coronary Artery Disease III: Clinical Manifestations